Japanese Trademark — JPO

The mark consists of two parallel lines curled into a helix; color is not a feature of the mark.

Application 2025359774 · 00

Quick Facts

Application Number	2025359774
Registration Number	1868311
Status	00
Mark (native)	The mark consists of two parallel lines curled into a helix; color is not a feature of the mark.
Mark Type	madrid
Owner	Constellation Pharmaceuticals, Inc.
Filed	2025-08-07
Registered	2025-02-03

Is this trademark active?

The mark consists of two parallel lines curled into a helix; color is not a feature of the mark. has a current status of 00.

Goods & Services

The specification below is taken directly from the filed record at the Japan Patent Office for each Nice class this trademark covers.

Class 1 — Chemicals

Antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways.

Class 5 — Pharmaceuticals

Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways.

Applicant

Name (romanised)

Constellation Pharmaceuticals, Inc.

Timeline

Filed: 2025-08-07
Registered: 2025-02-03

About This Trademark

'The mark consists of two parallel lines curled into a helix; color is not a feature of the mark.' is a 00 trademark on the Japan Patent Office register, owned by Constellation Pharmaceuticals, Inc.. The application (2025359774) was filed on 7 August 2025 and registered on 3 February 2025.

This mark is recorded under multiple classes: Class 1 (chemicals for industrial, scientific & agricultural use); Class 5 (pharmaceuticals & medical preparations), specifically covering: Antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways.; Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of blood diseases; pharmaceutical preparations for the treatment of diseases of the bone marrow; pharmaceutical preparations for the treatment of cancer, namely, BET protein inhibitors; pharmaceutical preparations for the treatment of myelofibrosis; pharmaceutical preparation for the treatment of myelodysplastic syndrome (MDS); pharmaceutical preparations for the treatment of myeloproliferative neoplasm; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for the treatment of thrombocythemia; pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceutical preparations comprising small molecules for treating cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; small molecule pharmaceuticals for the treatment of diseases and conditions, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; antibodies sold as a component ingredient of pharmaceuticals for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; diagnostic preparations for medical purposes; clinical medical reagents; biological preparations for medical purposes, namely for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways; pharmaceutical and veterinary preparations and agents for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases that involve dysregulation of epigenetic pathways.

Frequently Asked Questions

Who owns Japanese trademark 2025359774 ('The mark consists of two parallel lines curled into a helix; color is not a feature of the mark.')?

Japanese trademark 2025359774 for the mark 'The mark consists of two parallel lines curled into a helix; color is not a feature of the mark.' in Class 1, 5 is recorded on the Japan Patent Office register as owned by Constellation Pharmaceuticals, Inc.. This covers one specific Japanese trademark record only — the same brand name may be owned by different parties in other classes, other countries, or as separate registrations.

Is Japanese trademark 2025359774 currently a registered trademark?

No — the Japan Patent Office records the status of Japanese trademark 2025359774 for the mark 'The mark consists of two parallel lines curled into a helix; color is not a feature of the mark.' as 00.

Which Nice classes is Japanese trademark 2025359774 registered under?

Japanese trademark 2025359774 for the mark 'The mark consists of two parallel lines curled into a helix; color is not a feature of the mark.' is recorded in Class 1 (chemicals for industrial, scientific & agricultural use); Class 5 (pharmaceuticals & medical preparations). The filed specification reads: Class 1: Antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines for the treatment of cancer, myelofibrosis, myelodysplasic syndrome (MDS), myeloproliferative neoplasm, thrombocythemia, anemia, low-risk myelodysplasic syndrome (MDS), essential thrombocythemia (ET) and diseases tha…

When was Japanese trademark 2025359774 filed?

Japanese trademark 2025359774 for the mark 'The mark consists of two parallel lines curled into a helix; color is not a feature of the mark.' was filed at the Japan Patent Office on 7 August 2025 and registered on 3 February 2025.

Data Source

Japan (Japan Patent Office)

Japanese trademark data is supplied by the Japan Patent Office (JPO) via the JPO open bulk data release. Official government publications in Japan are not subject to copyright under Article 13 of the Japanese Copyright Act. Local copy last synchronised on 2026-05-02.

The “About This Trademark” summary and FAQ above are AI-generated from the register data shown on this page. They are factual summaries only — always verify details against the official register before making legal decisions.